Alkermes shares are trading higher after the company announced it entered into a settlement agreement with Teva Pharmaceuticals related to VIVITROL patent litigation.
Portfolio Pulse from Benzinga Newsdesk
Alkermes has entered into a settlement agreement with Teva Pharmaceuticals over VIVITROL patent litigation, leading to a rise in Alkermes' shares.
August 30, 2023 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alkermes' shares are trading higher after the company settled its VIVITROL patent litigation with Teva Pharmaceuticals.
The settlement of the patent litigation removes a significant legal risk for Alkermes, which is likely to be viewed positively by investors, leading to an increase in the company's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100